HKEX CEO: H.K. Unlikely to Get Advantage in China Data Reviews

The transcript discusses the biotech pipeline in Hong Kong, highlighting its growth since the introduction of Chapter 18 in 2018. Despite market volatility and regulatory scrutiny, the biotech sector remains vibrant with new technologies emerging. The discussion also covers the regulatory environment in China and the impact on biotech and other sectors. The comparison between Hong Kong and US listings is explored, noting the shift of some companies towards Hong Kong due to regulatory pressures. The future of biotech listings in Hong Kong is promising, with ambitions to become a leading capital-raising center. The role of international banks and potential risks, such as sanctions, are also considered.

What trends are being observed in the inquiries from companies considering listings in Hong Kong?

How does the current market environment affect the potential for new biotech listings?

What is the expected future of Hong Kong as a capital raising center for biotech companies?

What are the implications of the anti-sanctions law for international banks operating in Hong Kong?